Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.2359 -0.0106 (-4.30%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about FibroBiologics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
Platform Poised to Expand into Joint and Cartilage Repair 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Payoff of Outstanding Debt
Repayment of convertible promissory notes strengthens balance sheet and eliminates further dilution from conversions 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at Bio-Europe 2025
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the 2025 ThinkEquity Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment
Pilot studies underway to advance IND-enabling preclinical development 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Significant Advancements in Bone Marrow Organoid Platform Enabling Development for Cancer and Immune-Related Therapies
Pilot studies have shown encouraging results that are supporting the company’s pre-IND enabling development, marking a critical step toward clinical translation of the Bone Marrow Organoid technology 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
FibroBiologics to Present at the Advanced Wound Care Summit USA
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics to Present at the BIO International Convention 2025
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer
Seasoned finance executive brings over 20 years of public company and capital markets experience to support clinical-stage growth 
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting
From Fibrobiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the third... 
From Fibrobiologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.